How to boost participation in clinical studies
Insights

How digitalization can boost participation in clinical studies

By Daniel  Diezi  & Stefan Weiß &

Only about 5% of patients participate in clinical studies. Pharma and MedTech companies face time-consuming and costly processes when recruiting participants. Patient centric thinking in combination with digitalization can solve the problem.

Insight in brief

  • One major problem for pharma companies and medical device manufacturers is the recruitment of appropriate volunteers to participate in clinical studies.
  • An important reason why patients normally fail to participate in clinical studies is mainly due to the inconveniences they face.
  • With digital solutions like the mPower App, patients can participate in the clinical study whenever and wherever they want.
2 diagonalestriche lightgray

Regulatory authorities require that Pharma and MedTech companies provide clinical evidence that medical devices as well as new medicines deliver what they claim. These so called clinical studies are performed by enrolling volunteers to test the medicine or device. Without these scientific trials, new developments cannot get approval and consequently cannot obtain market access. Companies that have brought a new device or medicine as far as the starting point of a clinical study lose millions if the innovation cannot access the market.

There are a couple of severe and increasing challenges for the pharma and medical device companies with regards to clinical studies, including the increasing regulatory requirements, the need for international studies and the complexity and costs of these studies. The major problem, however, is the recruitment of appropriate volunteers to participate in clinical studies.

2 diagonalestriche lightgray

Patients without optimal care

As only about 5% of patients participate in clinical studies, pharmaceutical companies face a time-consuming and expensive recruitment process. As a result, around 80% of clinical studies fail to meet their enrolment deadlines and more than 35% of research sites do not reach their enrolment targets. For 10% of all clinical studies not even a single patient can be recruited, often because they target a specific condition which means there is a smaller patient population.

Additionally, the international requirements for clinical studies increase the obstacles even further, especially considering the fact that five billion people do not have access to proper health care. These issues result in delays and hinder the approval of new and innovative treatment options ultimately leaving patients without optimal care.

2 diagonalestriche lightgray

Digitalization meets patient centric thinking

They key question is: Why are patients so hard to recruit? There are some great examples that demonstrate the willingness of patients to participate in clinical studies. For example, the mPower App which allows the digital diagnosis of Parkinson’s disease to be performed by measuring the tremor using the phone’s internal accelerometer. The scientific team behind the App was able to recruit more than 7400 people for the clinical study in less than a day.

Interestingly, the main reason why patients normally fail to participate in clinical studies is mainly due to the inconveniences they face. The patient centric thinking of mPower is the first aspect to get it right Normally, patients would need to go regularly to health care providers for continuous testing, for example once a week to the hospital to give blood, have an examination or do some tests. These hurdles cause about every third patient to stop during the clinical study. With the mPower App, patients can participate in the clinical study whenever and wherever they want.

2 diagonalestriche lightgray

New virtual designs of clinical studies

Digitalization offers compelling benefits with regard to reaching the patients as the mPower App cleverly proved. Patients are even willing to share their data and they do so without getting any direct benefit. The pharmaceutical sector is on its way to becoming a data science company. But digitalization on its own hardly provides the solution to the issue. Digitalization is the tool that must be combined with patient centric thinking. Pharma and MedTech companies should engage and co-develop directly with patients in order to understand why they do not want to participate in clinical studies. Together with the patients, they need to find digital solutions that are convenient.

Digitalization offers not only new designs for clinical studies but also direct access to patients. About 60% of the African population has no access to health care as most people live in rural areas, but about 80% of the same population group can be contacted via a mobile phone. Through digitalization, new population groups can be involved in virtual clinical studies.

2 diagonalestriche lightgray

Broad technological expertise

Once patients are involved in the development process and the business case is understood, the technological feasibility needs to be addressed as well. Medically approved wearables and mobile technology require broad technological expertise: Involving skills in medical device and sensor development, secure web connections and Artificial Intelligence as well as intuitive visualization of insights. All these developments have to be embedded within an approved quality management system in alignment with ISO 13485.
 

Daniel Diezi

Daniel  Diezi 

Director Business Development & Head Health Industries  
Contact person for Switzerland daniel.diezi@zuehlke.com +41 31 561 3946 

When Daniel Diezi joined Zühlke in 2016, he already had acquired more than 12 years of global healthcare experience and led digital transformation projects internationally. As advisory board member of a digital health think-tank, the Swiss MedTech Association and as chairman of the MedTech & Pharma platform, he takes a leading role in shaping the future of health.

Stefan Weiß

Stefan Weiß

Lead Business Consultant
Contact person for Germany stefan.weiss@zuehlke.com +49 6196 777 54 426

Dr. Stefan Weiss is Lead Business Innovation Consultant at the Zühlke Group and has a broad background in Neuroscience combined with a profound expertise in economics and innovation management. Before joining Zühlke, Stefan shaped the future of Healthcare and Life Sciences at the Innovation Center of Merck KGaA. He is passionate about the digitalization of the Pharma- and MedTech Industry with innovative solutions and business models by applying his scientific and economic expertise. At Zühlke, he extends technical excellence with domain-specific insights and thereby strengthens the partnerships with Pharma- and MedTech customers